Celltrion, Inc. (068270.KS) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Celltrion, Inc., built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track 068270.KS live on Mooboard →

Later4

  • Dec 2026
    Celltrion, Inc.(068270.KS)Phase 2/3 readout
    Metformin · Phase 3 · T2DM; Diabete Type 2
    NCT07093476: Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin. Primary completion 2026-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 2027
    Celltrion, Inc.(068270.KS)Phase 2/3 readout
    CT-P51 · Phase 3 · Non Squamous Non Small Cell Lung Cancer
    NCT06939595: A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer. Primary completion 2027-02 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 2027
    Celltrion, Inc.(068270.KS)Phase 2/3 readout
    CT-P53 · Phase 3 · Relapsing-remitting Multiple Sclerosis
    NCT05906992: A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis. Primary completion 2027-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 15, 2027
    Celltrion, Inc.(068270.KS)Phase 2/3 readout
    CT-P44(Daratumumab) · Phase 3 · Refractory or Relapsed Multiple Myeloma
    NCT06952478: A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma. Primary completion 2027-11-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Celltrion, Inc. has moved — past-year price reactions

How binary is 068270.KS? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.2%
typical day (1Y)
2
±10% days
42%
annualized vol
242
trading days
Largest single-day moves
  • -12.3%2026-03-04no matched headline
  • +11.9%2026-01-02no matched headline
  • +8.9%2025-09-23no matched headline
  • +8%2026-06-29no matched headline
  • +7.6%2026-06-24no matched headline
  • +7.1%2026-03-05no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Celltrion, Inc. — active clinical pipeline

Celltrion, Inc.'s registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

6 assets6 programsPh1 1Ph2 0Ph3 5
AreasOncologyAutoimmuneNeuroscienceOther
CT-P44(Daratumumab)Oncology
Phase 3
Refractory or Relapsed Multiple Myeloma
CT-P51Oncology
Phase 3
Non Squamous Non Small Cell Lung Cancer
CT-P53Neuroscience
Phase 3
Relapsing-remitting Multiple Sclerosis
CT-P55Autoimmune
Phase 3
Plaque Psoriasis
MetforminOther
Phase 3
T2DM
IxekizumabOther · IL-17A
Phase 1
Healthy volunteers

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.